NATION-WIDE BREAST CANCER SCREENING IN THE NETHERLANDS: SUPPORT FOR BREAST-CANCER MORTALITY REDUCTION

National Evaluation Team for Breast Cancer Screening (NETB), consisting of: Harry J. de Koning1, Jacques Fracheboud2, Rob Boer1, André L.M. Verbeek1, Hubertine J.A. Collette2, Jan H.C.L. Hendriks3, B. Martin van Ineveld1, Anny E. de Bruijn1,4 and Paul J. van der Maas1 (Chairman)

1Dept. of Public Health, Erasmus Universiteit, Rotterdam; 2Dept. of Public Health and Epidemiology, Universiteit Utrecht; and 3Dept. of Epidemiology/Radiology, Katholieke Universiteit Nijmegen, Nijmegen, The Netherlands.

The nation-wide 2-yearly breast-cancer screening programme in The Netherlands, for women aged 50–69, started around 1988, and was predicted to result eventually in a 16% reduction in breast-cancer mortality in the total female population. We present the results of screening up to January 1, 1993, and compare these with the predicted results from the cost-effectiveness analysis, on which basis this mortality reduction had been calculated. At least 550,000 women aged 50–69 were invited to screening in 1990–1992, and 75% of these participated. Cancer was suspected from 5,162 examinations and further investigation was therefore required. Excision biopsy was done in 72% of referrals, and 2,515 breast cancers were detected. The results for 404,000 newly invited women compare favourably with expected values (in parentheses): 78% attendance rate (70%), 1.4% screen positive (1.6%), 6.8 cancers detected per 1,000 women screened (6.4) and 38% of these cancers were DCIS or invasive carcinomas smaller than 11 mm in diameter (36%). More data, e.g., on treatment and interval cancers, will follow in the years to come. These first results can be interpreted as strong early signs of a reduction in breast-cancer mortality of at least the predicted size. Screening has sufficiently advanced the diagnosis, as well as or better than expected. Breast cancers diagnosed in this age group without screening are diagnosed at a worse stage than expected. Unfavourable side-effects, especially false-positive referrals, might be kept lower than those reported in other countries.

MATERIAL AND METHODS

For the screening programme, The Netherlands has been divided into 9 regions, each with a joint management board, consisting of regional health authorities responsible for invitation of the women and of comprehensive cancer centres responsible for follow-up of data from cancer patients. In each region, a number of specialized (static, mobile or semi-mobile) screening units exists. Women receive a personal letter of invitation (fixed date) on the basis of the municipal population registries. Those women who do not respond receive a reminder. At the initial examination, 2-view mammography is performed, and at subsequent rounds 1-view. Films are developed immediately to enable the radiographer to decide whether an additional (cranial-caudal) view is required because of technical faults or difficulty in interpretation. The mammograms are evaluated independently by 2 radiologists at the central unit who have to reach consensus about advising referral. In case of suspicion of cancer, the woman is referred to her general practitioner who is responsible for further referral to an outpatient clinic for assessment, with standardized guidelines for screen-referred women. There is no self-referral system in the Dutch screening programme.

All regions use an information and registration system, and the regional joint management board is responsible for regional process evaluation and for reporting of regional results. The National Evaluation Team for Breast-cancer screening has defined a minimum dataset that is required for continuous outcome evaluation at national level. The data have been collected and analyzed annually by the Team since 1990. This report contains the data on population, invitations, screening, assessment and breast cancers diagnosed (by stage) in the years 1990–1992. Results are also reported separately for 1990–1991 and 1992 for any time trends. The very small number of newly screened women in 1988–1989 (approximately 10,000) is not taken into account here (de Koning et al., 1991). The data are compared with the estimates from the CE analysis, which was based on results of the randomized screening trials in Sweden and the trials in The Netherlands, using a validated breast-cancer screening model. The model takes into account the natural history of the disease, current epidemiologic knowledge, characteristics of the screening programme and possible regional differences. Finally, it is used to predict long-term reduction in mortality from early results.
of the programme, given estimates on improved prognosis for screen-detected cases obtained from randomized screening trials (van Oortmarssen et al., 1990; de Koning et al., 1991; Boet et al., 1994).

RESULTS

In the year 1990, 11% of the total target population (per year) was invited; in 1991 and 1992 25% and 49% respectively. In the first years of the national programme at least 550,630 women aged 50–69 were invited for breast cancer screening (Table I). Of these women, 72% took immediate action and attended screening, whereas 3% needed a reminder to participate (accepted recall). The total number of women screened was actually 470,000; approximately 54,000 were either 49 or 70 years old. Of the women aged 50–69, actually screened before January 1, 1993, 5,162 were referred for abnormalities suggestive of cancer. In 1,224 of these women, additional non-invasive procedures excluded a malignancy, while a further 3,713 (0.9% of screened women) underwent biopsy. In 2,515 women (2,689 aged 49–70), breast cancer was detected by screening. In 3.5% of the referred women, follow-up was not known or no additional procedures had been performed (about 1% were women who refused to be registered). In 86 cases the result of additional procedures (mostly non-invasive) was not yet known at time of analysis.

These results are influenced by the fact that some women have been invited for subsequent screens. The regions around Nijmegen and Utrecht had been part of the experimental projects since 1974–1975. In these areas, in 1991, 60% of all eligible women had already been invited at least once before. Table II subdivides the results for all regions together into “first screen” and “subsequent screens” (having had screening mammography earlier in the programme or in the experimental projects). The results for newly screened women are good: only 1.4% of women being referred for assessment without negatively influencing the detection rate (6.8 per 1,000), which is 3 times the clinical incidence rate (2.2 per 1,000). These early outcomes compare favourably with expectations. The expected average attendance rate of 70% is met, slightly less than expected on the basis of (fewer) data from non-screened, clinically diagnosed cases in Utrecht and Nijmegen (Table I). In the screen-detected group 14% of the cancers are ductal carcinomas in situ, and the non-invasive and small invasive cancers (up to 10 mm) amount to 38%. In the clinical setting, the latter would have been 16% only (expected). Clearly, less than 20% of the screen-detected cancers are invasive and larger than 2 cm in diameter. Only the smallest invasive size category (up to 5 mm) has been detected slightly less often than expected.

Another difference from the earlier expectations relates to the attendance rate by age category: a constantly decreasing trend by age had been seen in the earlier Dutch screening trials, consistent in each trial and through the years. In the present nation-wide programme, approximately 79% of newly invited women aged 50–64 attended screening and only in the oldest 65–69 category (newly invited) did it fall to 73%.

Screening significantly advances the diagnosis. Table III compares the histology and size distribution of all 2,143 screen-detected cancers in newly screened women (for the most part newly invited) to the distribution of 4,093 breast cancers diagnosed clinically in The Netherlands in 1989/1990 in this age group, as registered in the regions through regional cancer registries. The 4,093 cases comprise either clinically diagnosed cases in 1989/90 in regions that started screening in 1991, or all cases registered in 1990 excluding the screen-detected cancers in regions that had already started screening. Patients from the regions around Nijmegen and Utrecht with screening projects since the seventies are not included among the clinical cases.

In the screen-detected group 14% of the cancers are ductal carcinomas in situ, and the non-invasive and small invasive cancers (up to 10 mm) amount to 38%. In the clinical setting, the latter would have been 16% only (expected). Clearly, less than 20% of the screen-detected cancers are invasive and larger than 2 cm in diameter. Only the smallest invasive size category (up to 5 mm) has been detected slightly less often than expected.

Another factor of importance in mortality change is that the national stage distribution of breast cancer in The Netherlands in 1989, which has become available (Netherlands Cancer Registry, 1992), is likely to be less favourable than expected earlier on the basis of (fewer) data from non-screened, clinically diagnosed cases in Utrecht and Nijmegen (Table III last column).

DISCUSSION

The results of nation-wide breast cancer screening in The Netherlands meet, or in some cases exceed the predictions made before the programme started. Since the programme is able to detect the expected total number of breast cancers at a significantly earlier stage at the first screen, the evidence available up to now shows the predicted reduction of 16% in the breast cancer mortality of the total female population to be realistic (de Koning et al., 1991). Invasive cancers smaller than 11 mm in diameter or DCIS have been detected slightly more.
clear whether interval cancers will in general have a worse prognosis (Tabar et al., 1992). The small discrepancy regarding invasive cancers smaller than 5 mm in observed compared to expected percentages, in both screen-detected and clinically diagnosed cases, is likely to be due to classification problems during the ‘70–’80s in the Dutch trials.

In the years to come, more and other data are to be expected. Information about interval cancer rates from the nationally covered cancer registry(ies) as compared to the predicted rates will give a firm basis to decide whether the programme is able to detect a substantial proportion of all screen-detectable pre-clinical breast cancers. It already appears unlikely, from the detection rates and the size/histology distribution of screen-detected cases, that the interval cancer rate will be much different from that expected. It is not yet clear whether interval cancers will in general have a worse prognosis (Tabár et al., 1987; Ikeda et al., 1992), but with these first results presented, this is not expected to significantly influence the results on mortality reduction.

The first results are satisfying for several reasons. The invitation system is based on (100% covered) municipal population registries and recall of non-participants. The low referral rates, combined with the high predictive value of a referral, show that the number of false positives can be minimized, thus refuting one of the principal objections raised by opponents of screening. Unfavourable consequences are apparently being limited, by strict criteria for referral. In that respect, the results compare favourably with those of other countries where generally a 4–7% referral rate is found (Chamberlain et al., 1993), although it should be noted that 2-view mammography is used in the Dutch programme. Our results, like the regional UK results, indicate that high detection rates are not dependent upon relatively high referral rates. The impact on workload and cost is proportionally lower. The higher UK referral rate, if reproduced in the Netherlands, would cause an extra 2 million Dutch guilders ($1.2 million) annually for cost of assessment.

This analysis shows that the routine application of mammographic screening can attain quality levels that are comparable to those in experimental screening trials. We think that the use of specialized screening centres, the gradual build-up of the programme and the establishment of a National Expert and Training Centre for Breast Cancer Screening for the improvement of personnel and quality control have been decisive in attaining this result, together with the fact that extensive ‘reference’ predictions were available beforehand.

These early results do not make a continuous monitoring and continuous adjustment of predictions superfluous. These first years have already shown the need for interpreting regional differences in order to keep one uniform, high-quality programme running throughout the country. In the build-up period, in particular, it is important to learn from regional policies, for instance regarding invitations to see which one produces relatively high attendance rates. In this phase adaptations can still be made and useful advice for new screening centres given. More importantly, it will take years before a significant impact on breast cancer mortality can be expected and any reduction may be partly obscured by “autonomous” mortality changes. The small decrease in breast cancer mortality visible in Sweden since 1980–1984 (La Vecchia et al., 1992) may be due to the large number of Swedish screening trials on hand since the seventies, but it is not conclusive without information on stage distributions of all breast cancers diagnosed, screen-detected or not, and on changes in adjacent systemic treatment policy for all women with breast cancer diagnosed. It should be emphasized, also, that breast cancer screening is not an easy “export product” (Beemsterboer et al., 1994). Under optimal conditions, the balance between favour-
able and unfavourable effects for the participating women will tip toward the former and the cost-effectiveness ratio will be relatively favourable compared to other health care provisions. But in countries with a lower breast-cancer incidence, with different health-care systems or without the possibility of maintaining very high quality standards, the cost-effectiveness ratio may be much higher and, especially when high quality standards cannot be guaranteed, breast-cancer screening there might still do more harm than good.

ACKNOWLEDGEMENTS

We acknowledge the assistance of the individual evaluators in the 9 regions, of the Working Group Evaluation and the Coordinating Committee of the Health Insurance Executive Board, and of Mrs. P.M.M. Beemsterboer. Keeper of national data: Health Insurance Executive Board, Amstelveen. Regional data supplied by: Stichting Bevolkingsonderzoek Borstkanker Noord-Nederland, Groningen; Stichting Kankerpreventie IKA, Amsterdam; Stichting Vroege Opsporing Borstkanker, Enschede; Stichting Vroege Opsporing Borstkanker Midden-Nederland (Preventicon), Utrecht; Stichting Vroege Opsporing Kanker Oost-Nederland, Nijmegen; Stichting Kankerpreventie West-Nederland, Leiden; Stichting Bevolkingsonderzoek Borstkanker Zuid-West-Nederland, Rotterdam; Stichting Bevolkingsonderzoek Borstkanker Zuid, 's-Hertogenbosch; Stichting Kankerpreventie en screening Limburg, Maastricht.

REFERENCES


